Radiotherapy Devices Global Market Report 2024

The radiotherapy devices market size has grown rapidly in recent years. It will grow from $5.71 billion in 2023 to $6.29 billion in 2024 at a compound annual growth rate (CAGR) of 10.3%. The growth observed during the historical period can be attributed to factors such as the increasing incidence of cancer, a shift towards patient-centric care, the aging population, greater awareness of radiotherapy devices, and the expansion of teletherapy and remote monitoring in healthcare.

The radiotherapy devices market size is expected to see strong growth in the next few years. It will grow to $8.98 billion in 2028 at a compound annual growth rate (CAGR) of 9.3%. The anticipated growth in the forecast period can be attributed to factors such as the expansion of proton therapy, the combination of immunotherapy with radiotherapy, the increased adoption of remote monitoring and teletherapy, the rising demand for precise and targeted radiation treatments, and the development of minimally invasive radiotherapy techniques. Major trends expected in the forecast period include advancements in proton therapy, the utilization of hypofractionated radiotherapy, the implementation of adaptive radiotherapy, efforts to enhance the patient experience, and the integration of artificial intelligence (AI) in radiotherapy practices.

The growth of the radiotherapy devices market is being driven by the increasing prevalence of cancer. The term 'cancer prevalence' refers to the number or percentage of individuals within a population who have been diagnosed with cancer at a specific point in time or over a particular period. Radiotherapy is frequently utilized as a primary or supplementary treatment for newly diagnosed cancer patients. Its primary purposes include shrinking tumors, controlling cancer growth, and eliminating cancer cells, either before or after surgery. For example, as of February 2023, a report from the UK's House of Commons Library revealed that cancer claimed the lives of 134,802 individuals in England in 2021. Consequently, the rising prevalence of cancer is a significant driver of the radiotherapy devices market.

The primary product types of radiotherapy devices include external beam radiation therapy devices, linear accelerator devices (LINAC), and proton therapy devices. A medical linear accelerator, or LINAC, is a radiotherapy device typically employed for external beam radiation treatments in cancer patients. It delivers high-energy x-rays or electrons to the specific region of the patient's tumor. These devices find applications in treating various types of cancer, including skin cancer, breast cancer, prostate cancer, cervical cancer, lung cancer, and others. Radiotherapy devices are used in healthcare settings such as hospitals, ambulatory surgical centers, and oncological treatment centers.

The radiotherapy devices market research report is one of a series of new reports that provides radiotherapy devices market statistics, including radiotherapy devices industry global market size, regional shares, competitors with a radiotherapy devices market share, detailed radiotherapy devices market segments, market trends and opportunities, and any further data you may need to thrive in the radiotherapy devices industry. This radiotherapy devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth of the radiotherapy devices market is further boosted by the increasing number of clinical trials. Clinical trials are research investigations designed to assess the safety, effectiveness, and potential benefits of various medical treatments, interventions, drugs, medical devices, diagnostic procedures, and healthcare strategies in human subjects. These trials play a pivotal role in evaluating the safety and effectiveness of new radiotherapy devices. They involve the application of these devices on actual patients to ensure precise and intended radiation delivery. For instance, as of May 2023, there are 452,604 registered clinical studies, with 64,838 actively seeking participants, according to information from Xtalks, a Canadian digital health company. Therefore, the surge in clinical trials is propelling the growth of the radiotherapy devices market.

The high cost associated with radiotherapy procedures is expected to limit the market's growth. Radiotherapy involves the use of complex machinery and requires the expertise of skilled healthcare professionals. The overall cost of radiation therapy varies depending on factors such as the patient's location, the type of radiation treatment, and the number of required sessions. Proton therapy, a high-cost treatment, is typically conducted in metropolitan areas or major academic centers. It involves an eight-week treatment duration, resulting in substantial expenses for both the treatment and patient relocation. As per the National Cancer Institutes' report, the total national expenditure for cancer care in the United States amounted to approximately $150.8 billion. The high costs associated with cancer treatment can pose a significant challenge, particularly for individuals with limited insurance coverage or those without insurance. Hence, the high costs of radiotherapy procedures are expected to serve as a hindrance to market growth.

The integration of Artificial Intelligence (AI) is a prominent trend in the radiotherapy devices market and is rapidly gaining recognition. The introduction of AI innovations in cancer care is anticipated to enhance the precision and speed of diagnosis, aid in clinical decision-making, and yield improved treatment outcomes. For example, in October 2022, HCG Cancer Hospital launched an AI-based radiation treatment technology for efficient radiotherapy. Conventional treatment planning procedures, which can take several days to generate an optimized radiation treatment plan, are being expedited by these new AI advancements. Furthermore, AI is expected to find applications in deep learning for treatment planning, clinical decision support, automated image-guided adaptive radiation therapy, and the mining of genomic and radiobiological data, all of which will contribute to the market's growth.

Major companies operating in the radiotherapy devices market are actively innovating new technologies such as The Versa HD to enhance their market profitability. The Versa HD is a linear accelerator system designed for radiation therapy. For instance, in May 2023, the Mitchell Cancer Institute introduced a new radiation technology known as The Versa HD. This system is capable of delivering Volumetric Modulated Arc Therapy (VMAT), which accelerates treatment delivery and enhances the patient's experience. The Versa HD also provides High-Definition Dynamic Radiosurgery (HDRS), equipped with special sequencing capabilities, effectively transforming the linear accelerator into a specialized solution for Stereotactic Radiosurgery (SRS).

In July 2022, BEBIG Medical GmbH, a German-based radiotherapy treatment organization, acquired Wolf-Medizintechnik GmbH, a medical technology manufacturing company also based in Germany, for an undisclosed sum. This acquisition has enabled BEBIG Medical to expand its range of X-ray therapy devices for treating joint conditions and superficial skin cancers. It is expected to strengthen BEBIG Medical's position in the brachytherapy equipment market, which encompasses X-ray treatment devices, while expanding its product offerings to better serve its clients.

Major companies operating in the radiotherapy devices market include Varian Medical Systems Inc., Elekta AB, Accuray Incorporated, Becton Dickinson and Company, IBA Ion Beam Applications SA, Koninklijke Philips N.V., Siemens Aktiengesellschaft, Eckert & Ziegler Bebig, IsoRay Inc., General Electric Healthcare, Vision RT Ltd., RaySearch Laboratories AB, Theragenics Corporation, Canon Medical Systems Corporation, AngioDynamics Inc., Mitsubishi Electric Corporation, Shinva Medical Instrument Company Limited, Neusoft Medical Systems Co. Ltd., Mevion Medical Systems Inc., Optivus Proton Therapy Inc., Panacea Medical Technologies Pvt. Ltd., P-Cure Ltd., Provision Healthcare LLC, Sumitomo Heavy Industries Ltd., ViewRay Inc., Miranda Medical, Nordion Inc., NTP Radioisotopes SOC Ltd., Curium, Hitachi Ltd., Brainlab AG, Best Theratronics Ltd., ProTom International Inc., RefleXion Medical Inc., Insightec Ltd., HistoSonics Inc., Novocure Ltd., TomoTherapy Incorporated, Agile MV LLC, CIVCO Radiotherapy, Neutron Therapeutics, Diapulse Corporation of America, Johari Digital Healthcare Ltd., Alpha Tau Medical Ltd.

North America was the largest region in the radiotherapy devices market in 2023. Asia-Pacific was the second-largest region in the global radiotherapy devices market report. The regions covered in the radiotherapy devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the radiotherapy devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The radiotherapy devices market consists of sales of external beam radiation therapy devices, linear accelerator devices, and proton therapy devices that are used for radiotherapy. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.